Posts Tagged ‘product’
Frost & Sullivan Recognizes QRxPharma For Innovative Pain Relief Product MoxDuo
Based on its recent analysis of the opioid pain management market, Frost & Sullivan recognizes QRxPharma Limited with the 2010 North American Frost & Sullivan Award for New Product Innovation of the Year for MoxDuo® immediate-release (IR) (Q8003IR) the first patented dual opioid for the management of pain that also addresses some major challenges experienced by currently marketed opioids…
BioElectronics Receives New OTC Product Approvals
BioElectronics Corporation (PINKSHEETS: BIEL), developers of innovative pain-relieving medical devices, announced that its Allay™ Menstrual Pain Therapy product has been approved for over the counter sale by Health Canada for the treatment of menstrual pain symptoms, including cramps and abdominal pain, and for reducing the use of pain medication associated with menstruat…
Novel Intranasal Sumatriptan Product Highly Effective In Treating Migraines
OptiNose, a leader in nasal drug delivery systems, is pleased to announce the publication in Cephalalgia of results from its Phase II clinical study investigating the efficacy and tolerability of its novel, intranasal drug/device product for the treatment of migraine…
Covidien Launches Oral Transmucosal Fentanyl Citrate Product
Covidien (NYSE: COV), a leading global provider of healthcare products, today announced that Mallinckrodt Inc., a Covidien company, has launched its Oral Transmucosal Fentanyl Citrate (CII) to distributors serving retail pharmacies across the country. The U.S…
Covidien Receives FDA Approval For Oral Transmucosal Fentanyl Citrate Product
Covidien (NYSE: COV), a leading global provider of healthcare products, announced that its subsidiary, Mallinckrodt Inc., has received U.S. Food and Drug Administration (FDA) approval of its Abbreviated New Drug Application (ANDA) for Oral Transmucosal Fentanyl Citrate (CII). Covidien’s product is a generic alternative to the branded ACTIQ®. It is a solid formulation of fentanyl that resembles a lozenge on a handle.
Blue Cross Blue Shield Of Michigan Broadens Medicare Options With New Medicare Advantage PPO Product
Blue Cross Blue Shield of Michigan announced a new Medicare Advantage PPO product that for many Michigan seniors provides benefits at lower premiums than Original Medicare coupled with Part D drug plans and supplementary coverage. “Our new Medicare Advantage PPO provides the comprehensive coverage seniors want, including prescription drugs and benefits Original Medicare doesn’t provide,” said Mark Owen, BCBSM vice president for federal programs and individual business.
BD Announces Flu Product Order From U.S. Government
BD (Becton, Dickinson and Company) (NYSE:BDX) announced today that it has received a significant order from the Biomedical Advanced Research and Development Authority (BARDA) of the U.S. Department of Health and Human Services (HHS) for the purchase of syringes and needles, sharps collectors and alcohol swabs to be used in national flu pandemic preparedness efforts.
Studies Confirm That Arch Chemicals’ Vantocil FHC Antimicrobial Product Is Effective Against Swine Flu Virus
Arch Chemicals, Inc. announced today that research has demonstrated that its Vantocil? FHC antimicrobial product, which has long been used in hygiene applications in Europe and other global regions, is also highly effective in controlling the causative agent of swine flu, Swine Influenza A (H1N1) virus.
MAP Pharmaceuticals Phase 3 Trial Of Levadex? Migraine Product Candidate Meets All Four Primary Endpoints
MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) announced that the efficacy portion of its first Phase 3 clinical trial evaluating its novel LEVADEX? orally inhaled migraine therapy met all four primary endpoints. Additional endpoints showed that LEVADEX provided rapid and sustained pain relief for up to 48 hours after dosing.
MAP Pharmaceuticals Phase 3 Trial Of LEVADEX(TM) Migraine Product Candidate Meets All Four Primary Endpoints
MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) announced that the efficacy portion of its first Phase 3 clinical trial evaluating its novel LEVADEX(TM) orally inhaled migraine therapy met all four primary endpoints. Additional endpoints showed that LEVADEX provided rapid and sustained pain relief for up to 48 hours after dosing.
Rx Drug Compare
Translator
